Akero Therapeutics, Inc. financial data

Symbol
AKRO on Nasdaq
Industry
Pharmaceutical Preparations
Location
601 Gateway Boulevard, Suite 350, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.42K % +7.94%
Debt-to-equity 8.81 % -6.18%
Return On Equity -32.5 % -24.5%
Return On Assets -29.9 % -25.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 69.8M shares +25.3%
Common Stock, Shares, Outstanding 69.6M shares +25%
Entity Public Float 2.52B USD -99.3%
Common Stock, Value, Issued 7K USD +16.7%
Weighted Average Number of Shares Outstanding, Basic 69.4M shares +24.9%
Weighted Average Number of Shares Outstanding, Diluted 69.4M shares +24.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 232M USD +117%
General and Administrative Expense 37.7M USD +26.9%
Operating Income (Loss) -269M USD -97.4%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -237M USD -98.3%
Earnings Per Share, Basic -3.79 USD/shares -64.8%
Earnings Per Share, Diluted -3.79 USD/shares -64.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 316M USD +17.3%
Marketable Securities, Current 401M USD +40.7%
Cash, Cash Equivalents, and Short-term Investments 787M USD +28.4%
Assets, Current 747M USD +29.7%
Property, Plant and Equipment, Net 15K USD -25%
Operating Lease, Right-of-Use Asset 820K USD -23.2%
Other Assets, Noncurrent 108K USD -76.9%
Assets 818M USD +28.7%
Accounts Payable, Current 25.2M USD +120%
Employee-related Liabilities, Current 4.37M USD +28.3%
Liabilities, Current 43.3M USD +52.2%
Operating Lease, Liability, Noncurrent 605K USD -31.9%
Liabilities 79.2M USD +51.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 2.1M USD
Retained Earnings (Accumulated Deficit) -756M USD -45.7%
Stockholders' Equity Attributable to Parent 738M USD +26.6%
Liabilities and Equity 818M USD +28.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -35.1M USD -42.7%
Net Cash Provided by (Used in) Financing Activities 367M USD +2322%
Net Cash Provided by (Used in) Investing Activities 57.8M USD +229%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 69.6M shares +25%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 316M USD +17.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 768K USD +175%
Deferred Tax Assets, Valuation Allowance 177M USD +62.9%
Deferred Tax Assets, Gross 180M USD +64.2%
Operating Lease, Liability 888K USD -22.1%
Depreciation 1K USD -90.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -235M USD -95.3%
Lessee, Operating Lease, Liability, to be Paid 984K USD -25.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 351K USD +2.93%
Lessee, Operating Lease, Liability, to be Paid, Year One 341K USD +3.02%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 96K USD -44.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 208K USD -40.7%
Deferred Tax Assets, Operating Loss Carryforwards 88.2M USD +28.9%
Unrecognized Tax Benefits 3.39M USD +60.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 208K USD -40.7%
Operating Lease, Payments 329K USD +3.46%
Additional Paid in Capital 1.43B USD
Deferred Tax Assets, Net of Valuation Allowance 2.69M USD +241%
Share-based Payment Arrangement, Expense 28.6M USD +47.5%
Interest Expense 4.37M USD +40.3%